Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
diabetic retinopathy
Biotech
Phase 2 fail sends OcuTerra's eye drop dreams down the drain
OcuTerra's eye drops failed to improve disease severity or progression in a phase 2 diabetic retinopathy trial.
Gabrielle Masson
Mar 14, 2024 9:15am
Roche drops oral eye disease drug after completing phase 2
Oct 19, 2023 5:50am
Ocuphire's diabetic eye drug misses phase 2 primary endpoint
Jan 26, 2023 8:32am
Eye AI? Aye-aye, FDA tells AEYE
Nov 17, 2022 10:26am
Eyenuk scopes out $26M for diabetes eye screening AI
Oct 17, 2022 12:01pm
Digital Diagnostics dials up $75M for diabetic retinopathy AI
Aug 23, 2022 7:30am
